Post-exposure passive immunisation for preventing measles

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 4, 2014, Pages

  Young, Megan K ^a   Nimmo, Graeme R ^b   Cripps, Allan W ^c   Jones, Mark A ^d  

^a GRIFFITH UNIVERSITY   (Australia)

^b Department of Microbiology ^*  (Australia)

^c GRIFFITH UNIVERSITY   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

ADVERSE OUTCOME; CASE STUDY; DATA BASE; DEATH; DRUG EFFECT; DRUG EFFICACY; FEVER; HIGH RISK POPULATION; HUMAN; IMMUNOCOMPROMISED PATIENT; MEASLES; MUSCLE RIGIDITY; PASSIVE IMMUNIZATION; PATIENT SAFETY; PREGNANT WOMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RISK REDUCTION; SKIN REDNESS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; COHORT ANALYSIS; META ANALYSIS; POST EXPOSURE PROPHYLAXIS; PROCEDURES;

COHORT STUDIES; GAMMA-GLOBULINS; HUMANS; IMMUNIZATION, PASSIVE; MEASLES; POST-EXPOSURE PROPHYLAXIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84901499526     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010056.pub2     Document Type: Review

References (75)

1. Berkovich S, Starr S. Use of live-measles-virus vaccine to abort an expected outbreak of measles within a closed population. New England Journal of Medicine 1963;269(2):75-7.
2. Cockburn WC, Harrington JA. Gamma globulin in the prevention and attenuation of measles: controlled trials in day and residential nurseries. Lancet 1950;2(6641):732-6.
3. Degkwitz R. Over measles convalescent serum [Uber Masern-Rekonvaleszentenserum]. Zeitschrift fur Kinderheilkunde 1920;27:171-94.
4. Endo A, Izumi H, Miyashita M, Taniguchi K, Okubo O, Harada K. Current efficacy of postexposure prophylaxis against measles with immunoglobulin. Journal of Pediatrics 2001;138(6):926-8.
5. Glyn-Jones R. Measles vaccine gamma globulin in the prevention of cross infection with measles in an acute paediatric ward. Central African Journal of Medicine 1972;18(1):4-9.
6. Hartley P, Anderson T, Begg ND, Gunn W, Cruickshank R, Martin WJ, et al.Gamma-globulin in the prevention and attenuation of measles: report of a subcommittee to the blood transfusion research committee of the medical research council. Lancet 1948;2:41-4.
7. Morales EG, Mandry OC. Relative prophylactic value of convalescent and immune adult measles serums. American Journal of Diseases of Children 1930;39:1214-20.
8. Ordman CW, Jennings CG, Janeway CA. Chemical, clinical, and immunological studies on the products of human plasma fractionation. XII. The use of gamma globulin (human immune serum globulin) in the prevention and attenuation of measles. Journal of Clinical Investigation 1944;23(4):541-9.
9. Salomon G. The prophylactic injection of normal serum as a measles protection [Die prophylaktische Injektion von Normalserum als Masernschutz]. Deutsche Medizinische Wochenschrift 1923;49(35):1151-2.
10. Sheppeard V, Forssman B, Ferson MJ, Moreira C, Campbell-Lloyd S, Dwyer DE, et al.The effectiveness of prophylaxis for measles contacts in NSW. NSW Public Health Bulletin 2009;20(5-6):81-5.
11. Stillerman M, Marks HH, Thalhimer W. Prophylaxis of measles with convalescent serum: principal factors influencing the results. American Journal of Diseases of Children 1944;67(1):1-14.
12. Toomey JA. Prophylaxis of measles. American Journal of Diseases of Children 1926;32:401-6.
13. Wesselhoeft C, Gordon FF. Report of convalescent measles serum administration in cases exposed to measles during the course of scarlet fever and diptheria. New England Journal of Medicine 1928;198(14):752-4.
14. Barenberg LH, Lewis JM, Messer WH. Measles prophylaxis: comparative results with the use of adult blood, convalescent serum and immune goat serum (Tunnicliff). Journal of the American Medical Association 1930;95:4-8.
15. Benson WT, Lawrie JDH. The seroprophylaxis of measles. Edinburgh Medical Journal 1927;34:216-22.
16. Blackfan KD, Peterson MF, Conroy FC. Use of convalescent serum as a prophylaxis in measles and chickenpox. Ohio State Medical Journal 1923;19:97-100.
17. Christensen PE, Schmidt H. An epidemic of measles in southern Greenland 1951; measles in virgin soil. IV the significance of specific prophylaxis. Acta Medica Scandinavica 1953;145(2):126-42.
18. Gunn W. A critical investigation of the value of immune sera in the prophylaxis of measles. Lancet 1928;212(5484):690-4.
19. Haas SV, Blum J. The prophylactic value of blood of convalescents in measles. Journal of the American Medical Association 1926;87:558-61.
20. Karelitz S, Karelitz RF. The significance of the conditions of exposure in the study of measles prophylaxis: An added criterion in the evaluation of measles prophylactic agents. Journal of Pediatrics 1938;13:195-207.
21. King GE, Markowitz LE, Patriarca PA, Dales LG. Clinical efficacy of measles vaccine during the 1990 measles epidemic. Pediatric Infectious Disease Journal 1991;10(12):883-8.
22. Kingsbury AN. Serum prophylaxis in measles. An evaluation of the resulting immunity. Lancet 1927;209(5392):7-9.
23. Laning GM, Horan TN. Immune globulin used as preventive and modifier of measles. Journal of the Michigan State Medical Society 1935;34:772-4.
24. LeBlanc J, Stinchfield P. Measles outbreak management at a Minnesota Children's Hospital in 2011. American Journal of Infection Control 2012;40:e67.
25. Lempriere LR. Adult serum in a school epidemic of measles. British Medical Journal 1939;1:1136-7.
26. McGuinness AC, Stokes J, Armstrong JG. Vacuum dried human serums in the prevention and treatment of certain of the common communicable diseases - an 8-year study. American Journal of Medical Sciences 1943;205:826-34.
27. Monnet P, Levy M, Gilly R. Trial of prevention of measles by adult human plasma or placental gamma-globulins: addressing epidemics in the hospital environment [Essai de prevention de la rougeole par le plasma humain d'adultes ou les gamma-globulines d'origine placentaire: A propos d'epidemies en milieu hospitalier]. Pediatrie 1954;9(8):854-7.
28. Rivera ME, Mason WH, Ross LA, Wright HT. Nosocomial measles infection in a pediatric hospital during a community-wide epidemic. Journal of Pediatrics 1991;119:183-6.
29. Weaver GH, Crooks TT. The use of convalescent serum in the prophylaxis of measles. Journal of the American Medical Association 1924;82:204-6.
30. Zingher A. Convalescent whole blood, plasma and serum in prophylaxis of measles. Journal of the American Medical Association 1924;82:1180-7.
31. Australian Technical Advisory Group on Immunisation. The Australian Immunisation Handbook. Canberra: Australian Government, 2008.
32. Barrabeig I, Rovira A, Rius C, Munoz P, Soldevila N, Batalla J, et al.Effectiveness of measles vaccination for control of exposed children. Pediatric Infectious Disease Journal 2011;30:78-80.
33. Best, Voss, Roberts, Freeman. Starship Children's Health Clinical Guideline: Measles - Infection Control Definitions & Guidelines. www.adhb.govt.nz/starshipclinicalguidelines/_Documents/Measles.pdf (accessed 30 April 2012).
34. Birdsall HH. Antibodies. In: Mandell GL, Bennett JE, Dolin R editor(s). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 7th Edition. Philadelphia: Churchill Livingstone, 2009.
35. Black FL, Yannet H. Inapparent measles after gamma globulin administration. JAMA 1960;173(11):1183-8.
36. Castillo-Solorzano C, Reef S, Morice A, Andrus J, Ruiz M, Tambini G, et al.Guidelines for the documentation and verification of measles, rubella, and congenital rubella syndrome elimination in the region of the Americas. Journal of Infectious Diseases 2011;204(Suppl 2):683-9.
37. Centers for Disease Control and Prevention. Measles, mumps, and rubella - vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report 1998;47(RR-8):1-57.
38. Centers for Disease Control and Prevention. Increased transmission and outbreaks of measles - European Region, 2011. Morbidity and Mortality Weekly Report 2011;60:1605-10.
39. Centers for Disease Control and Prevention. General recommendations on immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report 2011;60(RR-2):1-61.
40. Communicable Diseases Network Australia. Measles: National Guidelines for Public Health Units. Canberra: Commonwealth Department of Health and Ageing, 2009.
41. Delaporte E, Richard J, Wyler Lazarevic C, Lacour O, Girard M, Ginet C, et al.Ongoing measles outbreak, Geneva, Switzerland, January to March 2011. Euro Surveillance: European Communicable Disease Bulletin 2011;16:10.
42. Division of Viral Diseases, National Centre for Immunization and Respiratory Diseases, CDC. Measles - United States, January - May 20, 2011. Morbidity and Mortality Weekly Report 2011;60(20):666-8.
43. European Medicines Agency. ICH Topic E 2 A - Clinical safety data management: definitions and standards for expedited reporting. www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002749.pdf (accessed 10 June 2010).
44. Gonik B. Passive immunization: the forgotten arm of immunologically based strategies for disease containment. American Journal of Obstetrics and Gynecology 2011;205(5):444.
45. Brozek J, Oxman A, Schunemann H. GRADEpro. 3.2 for Windows. Brozek J, Oxman A, Schunemann H, 2008.
46. Gustavo H, Dayan M, Rota J, Bellini W, Redd S. Chapter 7: Measles (updated April 2009). Manual for the Surveillance of Vaccine-Preventable Diseases. Atlanta: Centers for Disease Control and Prevention, 2008.
47. Heymann DL. Control of Communicable Diseases Manual. Washington DC: American Public Health Association, 2008.
48. Higgins J, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org 2011.
49. Hoskins R, Vohra R, Vlack S, Young MK, Humphrey K, Selvey C, et al.Multiple cases of measles after exposure during air travel - Australia and New Zealand, January 2011. Morbidity and Mortality Weekly Report 2011;60:851.
50. Health Protection Agency. Vaccination schedule: routine childhood immunisation schedule. www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/VaccineCoverageAndCOVER/VaccinationSchedule/ (accessed 2 January 2012).
51. Immunisation Department. Measles. Immunoglobulin Handbook. UK: Health Protection Agency, 2009.
52. Karelitz S, Greenwald CK, Klein AJ. Placental fluid in measles prophylaxis. Journal of Pediatrics 1937;10:170-4.
53. Keller M, Stiehm E. Passive immunity in prevention and treatment of infectious diseases. Clinical Microbiology Reviews 2000;13(4):602-14.
54. Martin R, Wassilak S, Emiroglu N, Uzicanin A, Deshesvoi S, Jankovic D, et al.What will it take to achieve measles elimination in the World Health Organization European Region: progress from 2003-2009 and essential accelerated actions. Journal of Infectious Diseases 2011;204(Suppl 1):325-34.
55. Moss W, Scott S. The Immunological Basis for Immunization Series Module 7: measles. Geneva: World Health Organization, 2009.
56. New Zealand Ministry of Health. Immunisation Handbook 2011. Wellington: Ministry of Health, 2011.
57. Parker Fiebelkorn A, Redd S, Gallagher K, Rota P, Rota J, Bellini W, et al.Measles in the United States during the postelimination era. Journal of Infectious Diseases 2010;202(10):1520-8.
58. Ramsay M, Manikkavasagan G, Brown K, Craig L. Post exposure prophylaxis for measles: revised guidance May 2009. Health Protection Agency, UK 2009.
59. Reading SA, Dimmock NJ. Neutralization of animal virus infectivity by antibody. Archives of Virology 2007;152:1047-59.
60. Sawyer L. Antibodies for the prevention and treatment of viral diseases. Antiviral Research 2000;47(2):57-77.
61. Smithson R, Irvine N, Hutton C, Doherty L, Watt A. Spotlight on measles 2010: ongoing measles outbreak in Northern Ireland following an imported case, September-October 2010. Euro Surveillance: European Communicable Disease Bulletin 2010;15:43.
62. Sniadack D, Mendoza-Aldana J, Jee Y, Bayutas B, Lorenzo-Mariano K. Progress and challenges for measles elimination by 2012 in the Western Pacific Region. Journal of Infectious Diseases 2011;204(Suppl 1):439-46.
63. Stokes J, Maris E, Gellis S. Chemical, clinical, and immunological studies on the products of human plasma fractionation. XI. The use of concentrated normal human serum gamma globulin (human immune serum globulin) in the prophylaxis and treatment of measles. Journal of Clinical Investigation 1944;23(4):531-40.
64. Takimoto N, Takahashi Y, Ishiyama A, Kishimoto K, Iwama R, Nakano M. Control of a measles outbreak by prohibiting non-vaccinated susceptible students from attending school in Akita Prefecture, Japan. Japanese Journal of Infectious Diseases 2011;64(4):309-11.
65. Thalhimer W, Stillerman M. Prevention and modification of measles with concentrated pooled ascites fluid and with its globulin fraction. Proceedings of the Society for Experimental Biology and Medicine 1939;42:683-7.
66. UK Department of Health. Chapter 21: Measles - updated December 2010. Immunisation Against Infectious Disease - "The Green Book". UK: Department of Health, UK, 2006.
67. Vainio K, Ronning K, Steen T, Arnesen T, Anestad G, Dudman S. Ongoing outbreak of measles in Oslo, Norway, January - February 2011. Euro Surveillance: European Communicable Disease Bulletin 2011;16:8.
68. World Health Organization, Communicable Disease Surveillance and Response. WHO Guidelines for Epidemic Preparedness and Response to Measles Outbreaks. www.who.int/csr/resources/publications/measles/whocdscsrisr991.pdf (accessed 10 June 2012).
69. World Health Organization, UNICEF. GIVS: Global Immunization Vision and Strategy 2006-2015. Switzerland: WHO and UNICEF, 2005.
70. World Health Organization. Progress towards reducing measles mortality and eliminating measles, WHO Eastern Mediterranean Region, 1997-2007. Weekly Epidemiological Record 2008;83(11):97-104.
71. World Health Organization. Measles vaccines: WHO position paper. Weekly Epidemiological Record 2009;84(35):349-60.
72. World Health Organization. Global reductions in measles mortality 2000-2008 and the risk of measles resurgence. Weekly Epidemiological Record 2009;84(49):509-16.
73. World Health Organization. Progress in global measles control, 2000-2010. Weekly Epidemiological Record 2012;87(5):45-52.
74. World Health Organization. Global health observatory data repository: World Health Statistics - selected infectious diseases, measles number of reported cases, data by WHO region. http://apps.who.int/gho/data/view.main.1520_62?lang=en (accessed 21 March 2014) 2013 (accessed 21 March 2014).
75. World Health Organization. WHO Vaccine Preventable Diseases Monitoring System 2013 Global Summary. http://apps.who.int/immunization_monitoring/globalsummary (accessed 21 March 2014) 2014.